| Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis CJL Murray, KS Ikuta, F Sharara, L Swetschinski, GR Aguilar, A Gray, ... The lancet 399 (10325), 629-655, 2022 | 10022 | 2022 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2176* | 2021 |
| The 2018 Lake Louise acute mountain sickness score RC Roach, PH Hackett, O Oelz, P Bärtsch, AM Luks, MJ MacInnis, ... High altitude medicine & biology 19 (1), 4-6, 2018 | 1428 | 2018 |
| High-altitude illness B Basnyat, DR Murdoch The Lancet 361 (9373), 1967-1974, 2003 | 730 | 2003 |
| Acute high-altitude illnesses P Bärtsch, ER Swenson New England Journal of Medicine 368 (24), 2294-2302, 2013 | 546 | 2013 |
| Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events VK Wong, S Baker, DJ Pickard, J Parkhill, AJ Page, NA Feasey, ... Nature genetics 47 (6), 632-639, 2015 | 499 | 2015 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 466* | 2021 |
| Antimicrobial Drug Resistance of Salmonella enterica Serovar Typhi in Asia and Molecular Mechanism of Reduced Susceptibility to the Fluoroquinolones TT Chau, JI Campbell, CM Galindo, N Van Minh Hoang, TS Diep, ... Antimicrobial agents and chemotherapy 51 (12), 4315-4323, 2007 | 334 | 2007 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 272 | 2022 |
| The etiology of febrile illness in adults presenting to Patan hospital in Kathmandu, Nepal DR Murdoch, CW Woods, MD Zimmerman, PM Dull, RH Belbase, ... American Journal of Tropical Medicine and Hygiene 70 (6), 670-675, 2004 | 259 | 2004 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 257 | 2022 |
| Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the … M Naghavi, KL Ong, A Aali, HS Ababneh, YH Abate, C Abbafati, ... The Lancet 403 (10440), 2100-2132, 2024 | 251 | 2024 |
| Salmonella enterica Serovar Paratyphi A and S. enterica Serovar Typhi Cause Indistinguishable Clinical Syndromes in Kathmandu, Nepal AP Maskey, JN Day, PQ Tuan, GE Thwaites, JI Campbell, M Zimmerman, ... Clinical infectious diseases 42 (9), 1247-1253, 2006 | 249 | 2006 |
| Admixture facilitates genetic adaptations to high altitude in Tibet C Jeong, G Alkorta-Aranburu, B Basnyat, M Neupane, DB Witonsky, ... Nature communications 5 (1), 3281, 2014 | 225 | 2014 |
| Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries M Mendelson, JA Røttingen, U Gopinathan, DH Hamer, H Wertheim, ... The Lancet 387 (10014), 188-198, 2016 | 216 | 2016 |
| Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions G Parati, P Agostoni, B Basnyat, G Bilo, H Brugger, A Coca, L Festi, ... European heart journal 39 (17), 1546-1554, 2018 | 213 | 2018 |
| A current perspective on antimicrobial resistance in Southeast Asia RM Zellweger, J Carrique-Mas, D Limmathurotsakul, NPJ Day, ... Journal of Antimicrobial Chemotherapy 72 (11), 2963-2972, 2017 | 200 | 2017 |
| Genome-wide association study identifies five new susceptibility loci for primary angle closure glaucoma CC Khor, T Do, H Jia, M Nakano, R George, K Abu-Amero, R Duvesh, ... Nature genetics 48 (5), 556-562, 2016 | 200 | 2016 |
| Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial B Basnyat, JH Gertsch, EW Johnson, F Castro-Marin, Y Inoue, C Yeh High Altitude Medicine & Biology 4 (1), 45-52, 2003 | 192 | 2003 |
| Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of … JH Gertsch, B Basnyat, EW Johnson, J Onopa, PS Holck Bmj 328 (7443), 797, 2004 | 188 | 2004 |
